Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OAT | P04181 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4446964 | 0.91 | SMN1; SMN2 (0.39) | GAATDP1L3MBTL1SMN1; SMN2OAT | |
| Trifluoroacetic Acid SCHEMBL15542135 | 0.88 | OAT (0.35) | GAATDP1L3MBTL1OAT | |
| Trifluoroacetic Acid SCHEMBL3900743 | 0.88 | OAT (0.35) | GAATDP1L3MBTL1OAT | |
| Trifluoroacetic Acid SCHEMBL3154232 | 0.87 | OAT (0.35) | L3MBTL1OAT | |
| Trifluoroacetic Acid SCHEMBL28133460 | 0.87 | OAT (0.35) | L3MBTL1OAT | |
| SCHEMBL482012 | 0.84 | SMN1; SMN2 (0.43) | GAATDP1L3MBTL1SMN1; SMN2KDM4E | |
| Trifluoroacetic Acid SCHEMBL3025153 | 0.84 | OAT (0.36) | L3MBTL1OAT | |
| SCHEMBL8228115 | 0.84 | SMN1; SMN2 (0.43) | GAATDP1L3MBTL1SMN1; SMN2KDM4E | |
| SCHEMBL61731 | 0.84 | SMN1; SMN2 (0.43) | GAATDP1L3MBTL1SMN1; SMN2KDM4E | |
| Trifluoroacetic Acid SCHEMBL28336846 | 0.83 | KDM4E (0.42) | GAATDP1L3MBTL1SMN1; SMN2OAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| CN-101426482-A | Purine derivatives for use as adenosin A2A receptor agonists | NOVARTIS AG (CH) | 2009-05-06 | — | — | CN | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-2012759-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2007121923-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | GAA 2483/4885TDP1 3161/4885L3MBTL1 4781/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | GAA 3626/4885TDP1 3659/4885L3MBTL1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.